Archaea influence composition of endoscopically visible ileocolonic biofilms
Elisabeth Orgler,
Maximilian Baumgartner,
Stefanie Duller,
Christina Kumptisch,
Bela Hausmann,
Doris Moser,
Vineeta Khare,
Michaela Lang,
Thomas Köcher,
Adrian Frick,
Markus Muttenthaler,
Athanasios Makristathis,
Christine Moissl-Eichinger,
Christoph Gasche
Affiliations
Elisabeth Orgler
Division of Gastroenterology and Hepatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
Maximilian Baumgartner
Division of Gastroenterology and Hepatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
Stefanie Duller
Diagnostic and Research Center for Molecular BioMedicine, Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria
Christina Kumptisch
Diagnostic and Research Center for Molecular BioMedicine, Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria
Bela Hausmann
Centre for Microbiology and Environmental Systems Science, Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria
Doris Moser
Department of Cranio-Maxillofacial and Oral Surgery, Medical University of Vienna, Vienna, Austria
Vineeta Khare
Division of Gastroenterology and Hepatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
Michaela Lang
Division of Gastroenterology and Hepatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
Thomas Köcher
Metabolomics Service and Research Facility, Vienna Biocenter Core Facilities, Vienna, Austria
Adrian Frick
Division of Gastroenterology and Hepatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
Markus Muttenthaler
Faculty of Chemistry, Institute of Biological Chemistry, University of Vienna, Vienna, Austria
Athanasios Makristathis
Centre for Microbiology and Environmental Systems Science, Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria
Christine Moissl-Eichinger
Diagnostic and Research Center for Molecular BioMedicine, Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria
Christoph Gasche
Division of Gastroenterology and Hepatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
The gut microbiota has been implicated as a driver of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Recently we described, mucosal biofilms, signifying alterations in microbiota composition and bile acid (BA) metabolism in IBS and ulcerative colitis (UC). Luminal oxygen concentration is a key factor in the gastrointestinal (GI) ecosystem and might be increased in IBS and UC. Here we analyzed the role of archaea as a marker for hypoxia in mucosal biofilms and GI homeostasis. The effects of archaea on microbiome composition and metabolites were analyzed via amplicon sequencing and untargeted metabolomics in 154 stool samples of IBS-, UC-patients and controls. Mucosal biofilms were collected in a subset of patients and examined for their bacterial, fungal and archaeal composition. Absence of archaea, specifically Methanobrevibacter, correlated with disrupted GI homeostasis including decreased microbial diversity, overgrowth of facultative anaerobes and conjugated secondary BA. IBS-D/-M was associated with absence of archaea. Presence of Methanobrevibacter correlated with Oscillospiraceae and epithelial short chain fatty acid metabolism and decreased levels of Ruminococcus gnavus. Absence of fecal Methanobrevibacter may indicate a less hypoxic GI environment, reduced fatty acid oxidation, overgrowth of facultative anaerobes and disrupted BA deconjugation. Archaea and Ruminococcus gnavus could distinguish distinct subtypes of mucosal biofilms. Further research on the connection between archaea, mucosal biofilms and small intestinal bacterial overgrowth should be performed.